02/05/2026
After a bruising year that wiped out over $1.2 billion in value, South African billionaire Stephen Saad is staging a remarkable comeback, and so is his pharma empire, Aspen Pharmacare.
The Durban-based drugmaker has rebounded sharply on the Johannesburg Stock Exchange, lifting Saad’s stake by R1.5 billion ($87.14 million) to nearly $500 million. This follows a turbulent 2025 marked by regulatory setbacks, a costly mRNA dispute, and one of the steepest single-day stock drops in over two decades.
But here’s the twist: while investors pulled back, Stephen Saad doubled down, accumulating more shares and reinforcing his long-term conviction in Aspen Pharmacare. That bold bet is now paying off, with the company’s market capitalization rebounding to R62 billion ($3.72 billion) on the Johannesburg Stock Exchange.
Looking ahead, Shore.Africa anticipates a potential return to the $5 billion mark as a key signal of stronger shareholder value. While the current rally has yet to fully erase prior losses, the near 26% gain so far in 2026 points to renewed momentum and a recovery story that’s steadily regaining investor confidence.
This isn’t just a recovery story; it’s a masterclass in resilience, confidence, and the long game in Africa’s pharmaceutical sector.
📌Tap the comment below to read the full story.